<p>Bronchiectasis is a chronic respiratory condition characterized by permanent enlargement and damage to the airways, leading to mucus buildup, recurrent infections, and impaired airway clearance. It can be classified into two types: non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis (CF) bronchiectasis. Symptoms include chronic cough, sputum production, and frequent respiratory infections. It can be caused by a variety of factors such as infections, autoimmune diseases, and genetic conditions. Early diagnosis and treatment are essential for managing symptoms and preventing disease progression.</p>
<h2><strong>Bronchiectasis Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Bronchiectasis in the 7MM (United States, EU5&mdash;Germany, France, Italy, Spain, and the United Kingdom&mdash;and Japan) from 2023 to 2034 includes:</p>
<ul>
<li>Total Diagnosed Prevalent Cases of NCFB</li>
<li>Gender-specific Diagnosed Prevalent Cases of NCFB</li>
<li>Severity-specific Diagnosed Prevalent Cases of NCFB</li>
<li>Etiology-specific Diagnosed Prevalent Cases of NCFB</li>
<li>Microbiology of NCFB Patients</li>
<li>Total Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis</li>
<li>Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis</li>
<li>Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis Bronchiectasis</li>
<li>Microbiology of Cystic Fibrosis Bronchiectasis Patients</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/bronchiectasis-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Bronchiectasis Epidemiology</strong></span></a></h2>
<ul>
<li>In 2023, the total diagnosed prevalent cases of non-cystic fibrosis bronchiectasis (NCFB) across the 7MM were approximately 1,028,651. This number is expected to rise during the forecast period (2024&ndash;2034), driven by increased awareness and screening, as well as advancements in diagnostic techniques.</li>
<li>In the United States, there were approximately 380,711 diagnosed prevalent cases of NCFB in 2023, and this number is projected to rise over the forecast period.</li>
<li>Among EU4 and the UK, the UK reported the highest number of diagnosed prevalent cases of NCFB with 224,976 cases, followed by Spain (149,236 cases) and Italy (89,584 cases).</li>
<li>Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases.</li>
<li>In the UK, gender-specific cases of NCFB in 2023 showed approximately 130,486 cases in females and 94,490 cases in males.</li>
<li>In Japan, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to other pathogens, accounting for 46,600 cases in 2023.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/bronchiectasis-market-insight"><span style="text-decoration: underline;"><strong>Bronchiectasis Market</strong></span></a></h2>
<p>The total market size for bronchiectasis in the 7MM was approximately USD 1,581.2 million in 2023 and is projected to increase during the forecast period (2024&ndash;2034), with a compound annual growth rate (CAGR) of approximately 10.2%.</p>
<h2>Bronchiectasis Market Drivers</h2>
<ul>
<li>Increased Awareness and Screening: As awareness of bronchiectasis increases and diagnostic techniques improve, more patients are expected to be diagnosed, leading to market growth.</li>
<li>Rising Demand for Effective Therapies: There is a growing demand for treatments that can help manage bronchiectasis symptoms, reduce exacerbations, and improve the quality of life for patients, which drives the market forward.</li>
</ul>
<h2>Bronchiectasis Market Barriers</h2>
<ul>
<li>Limited Treatment Options: Despite recent progress, there are still limited disease-modifying treatments available for bronchiectasis, hindering market growth.</li>
<li>Cost and Accessibility: High treatment costs and limited access to specialized care in certain regions may present barriers to effective disease management, especially in low-resource settings.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/bronchiectasis-pipeline-insight"><span style="text-decoration: underline;"><strong>Bronchiectasis Emerging Therapies</strong></span></a></h2>
<ul>
<li>Brensocatib</li>
<li>CMS I-neb</li>
<li>FASENRA</li>
</ul>
<p>and others</p>
<h2><strong>Bronchiectasis Key Players</strong></h2>
<ul>
<li>Insmed</li>
<li>AstraZeneca</li>
<li>Zambon</li>
<li>Renovion</li>
<li>Haisco Pharmaceutical Group</li>
<li>Chiesi Farmaceutici S.p.A</li>
<li>Armata Pharmaceuticals</li>
<li>Verona Pharma</li>
<li>Sanofi</li>
<li>Regeneron Pharmaceuticals</li>
<li>Boehringer Ingelheim</li>
<li>CSL</li>
</ul>
<p>and others</p>

Bronchiectasis Market Infographic

Bronchiectasis Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.